Elicio Therapeutics, Inc.

Elicio Therapeutics, Inc.

1.34
EUR
-0.02
(-1.47%)
-1.55EPS
45.57MMarket Cap
Mar 26Next Earn

Total Valuation

EUR

As of September 30, 2026, Elicio Therapeutics, Inc carries a market capitalization of 45.57M, placing it among publicly traded companies globally. Its enterprise value stands at 30.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap45.57M
Enterprise Value30.66M

Important Dates

Elicio Therapeutics, Inc's next confirmed earnings release is scheduled for March 26, 2027.

Earnings Date3/26/2027

Share Statistics

As of September 30, 2026, Elicio Therapeutics, Inc has 28.31M shares outstanding.

Shares Outstanding28.31M

Valuation Ratios

These figures are as of September 30, 2026.

PB Ratio2.74
P/TBV Ratio2.74
P/FCF Ratio-1.01
P/OCF Ratio-1.01

Financial Position

As of September 30, 2026, Elicio Therapeutics, Inc maintains a current ratio of 3.43, meaning it holds 3.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 74.22, indicating elevated leverage, while an interest coverage ratio of -23.73 demonstrates limited ability to service its debt obligations.

Current Ratio3.43
Quick Ratio3.11
Debt / Equity74.22
Debt / EBITDA-0.38
Interest Coverage-23.73

Financial Efficiency

Over the twelve months ended September 30, 2026, Elicio Therapeutics, Inc posted a negative return on equity (ROE) of -315.32, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -105.29, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 33.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-315.32
Return on Assets (ROA)-105.29
Employee Count33.00

Taxes

EUR

Over the twelve months ended September 30, 2026, Elicio Therapeutics, Inc recorded 48,526.50 in income tax expense. The company reported a pretax loss of -31.48M and -31.53M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax48,526.50

Stock Price Statistics

EUR

As of the close on November 17, 2026, Elicio Therapeutics, Inc's stock has declined approximately 82.25% over the past 52 weeks. The 50-day moving average sits at 1.58, while the 200-day moving average is 5.42.

52-Week Price Change-82.25%
50-Day Moving Average1.58
200-Day Moving Average5.42

Income Statement

EUR

Over the twelve months ended September 30, 2026, Elicio Therapeutics, Inc generated - - in revenue and converted that into -31.53M in net income, yielding earnings per share of -1.55. EBITDA reached -32.81M, while operating income came in at -33.81M.

Operating Income-33.81M
Pretax Income-31.48M
Net Income-31.53M
EBITDA-32.81M
EBIT-33.81M
Earnings Per Share (EPS)-1.55

Balance Sheet

EUR

As of September 30, 2026, Elicio Therapeutics, Inc holds 27.26M in cash and equivalents against 12.34M in total debt, resulting in a net debt position of -18.76M. Total book value stands at 16.63M, with working capital of 21.27M providing operational flexibility.

Cash & Cash Equivalents27.26M
Total Debt12.34M
Net Debt-18.76M
Equity (Book Value)16.63M
Book Value Per Share0.59
Working Capital21.27M

Cash Flow

EUR

Elicio Therapeutics, Inc produced -32.62M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -14,116.80 in capital expenditures, free cash flow totaled -32.63M - equivalent to -1.60 per share.

Operating Cash Flow-32.62M
Capital Expenditures-14,116.80
Free Cash Flow-32.63M
FCF Per Share-1.60

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -99.42: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -91.35, meaning Elicio Therapeutics, Inc raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-91.35
FCF Yield-99.42

Stock Splits

Elicio Therapeutics, Inc's most recent stock split took place on June 2, 2023 with a 10:1 split ratio.

Last Split Date6/2/2023
Split Ratio10:1

Scores

As of September 30, 2026, Elicio Therapeutics, Inc has an Altman Z-Score of -10.22, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-10.22